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Currently, therapy of black-grain mycetoma caused byMadurella mycetomatis consists of extensive debridement of the infected
tissue combined with prolonged antifungal therapy with ketoconazole or itraconazole. In the present study, the in vitro activity
of the new triazole isavuconazole towardM. mycetomatiswas evaluated. Isavuconazole appeared to have high activity againstM.
mycetomatis, withMICs ranging from<0.016 to 0.125g/ml. Due to its favorable pharmacokinetics, isavuconazole could be a
promising antifungal agent in the treatment of mycetoma.
Madurella mycetomatis is themost common causative agent ofeumycetoma. This chronic, granulomatous infection is of-
ten found in the lower extremities, but it has been reported in
other parts of the body as well (4). The infection starts as a small
subcutaneous nodule, which gradually progresses into chronic in-
flammatory lesions with multiple sinuses that excrete a purulent
and seropurulent discharge containing black grains. To date,
treatment of eumycetoma in areas where eumycetoma is endemic
consists of a combination of extensive mutilating surgery or am-
putation of the infected tissue or limb and prolonged antifungal
therapy with ketoconazole or itraconazole (1). However, eumyce-
toma is associated with high recurrence rates, even after amputa-
tion of the affected limb. ForM. mycetomatis, the susceptibility to
antifungal agents belonging to the classes of polyenes, azoles, ally-
lamines, and echinocandins has been determined (3, 18, 20). Data
from these studies suggest thatM. mycetomatis is susceptible only
to antifungal agents that interfere with ergosterol synthesis. Low
MICs were obtained for the azoles.
Currently, isavuconazole is under development as a new azole
for the treatment of invasive fungal infections. No in vitro suscep-
tibility data of isavuconazole towardM.mycetomatis are available.
In this study, the in vitro activity of isavuconazole toM.mycetoma-
tis is evaluated by determining the MICs of 22 M. mycetomatis
strains (obtained from 21 patients in the Mycetoma Research
Centre, University of Khartoum, Sudan, in 1999 and 2000) in du-
plicate. The strains were identified previously by morphology, PCR-
restriction fragment length polymorphism (RFLP), and internal
transcribed spacer (ITS) sequencing (2, 19). MICs were determined
by using the 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenyl-
amino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay (3). In
brief, M. mycetomatis colonies were inoculated in RPMI 1640 me-
dium containing 0.35 g/liter L-glutamine and 1.98 mM 4-morpho-
linepropanesulfonic acid, sonicated (5 s at 28-mmaximumpower,
Beun de Ronde, TheNetherlands), and incubated for 7 days at 37°C.
The mycelia were harvested by another sonication step and 5-min
centrifugation at 2,628 g. The pellet was washed and resuspended
in sterile saline, and the fungal suspensionwas adjusted to 70%trans-
mission at 660 nm (Novaspec II; Pharmacia Biotech). The drug con-
centrations tested ranged from 0.016 g/ml to 16 g/ml isavucona-
zole. As comparator agents, ketoconazole and itraconazole were
tested at the same concentrations. XTTwas administered to facilitate
endpoint reading. MICs were determined spectrophotometrically
and defined as the lowest concentration of antifungal agent where at
least an 80% growth reduction was measured. Candida parapsilosis
(ATCC 22019) was included in the study as a quality control strain.
In concordance with previously published data,M.mycetoma-
tis was strongly inhibited by low concentrations of ketoconazole
and itraconazole (18), the antifungal agents currently used to treat
mycetoma in the areas where mycetoma is endemic. MICs for
ketoconazole and itraconazole ranged from 0.031 g/ml to 1
g/ml and 0.016 g/ml to 0.25 g/ml, respectively (Fig. 1).
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FIG 1 In vitro susceptibilities of 22 Madurella mycetomatis isolates to isavu-
conazole (ISA), ketoconazole (KTC), and itraconazole (ITC), according to the
XTT assay.
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Concentrations of 0.25 g/ml and 0.125 g/ml were needed to
inhibit 90%of the isolates (MIC90) for ketoconazole and itracona-
zole, respectively (Table 1). Compared to ketoconazole, signifi-
cantly lowerMICs were obtained for isavuconazole, ranging from
0.016 g/ml to 0.125 g/ml, with a MIC90 of 0.063 g/ml
(Mann-Whitney, P  0.018). Compared to previously deter-
minedMICs of posaconazole (18) and voriconazole (20),MICs of
isavuconazole were significantly lower than those of voriconazole
(P 0.0002) but not those of posaconazole.
The in vitro susceptibility ofM.mycetomatis to isavuconazole is
comparable to that of Exophiala spp., also a well-known cause of
black-grain mycetoma (6). In contrast, white-grain mycetoma
agents, like Pseudallescheria boydii and Fusarium spp., have higher
MICs of isavuconazole thanM. mycetomatis does (6, 10). Various
studies on the in vitro activity of isavuconazole onAspergillus spp.,
Candida spp., Cryptococcus neoformans, Cryptococcus gatii, and
other fungi conclude that isavuconazole has at least similar or
better activity than comparable antifungal compounds, like po-
saconazole and voriconazole (5–9, 12, 13, 16, 17, 21). Isavucona-
zole has even shown high activity against Aspergillus spp. resistant
to itraconazole, caspofungin, and amphotericin B (21) and to
Candida spp. resistant to fluconazole (24). In addition, in in vivo
animal models of fungal infections, such as invasive aspergillosis
and disseminated candidiasis, isavuconazole showed good thera-
peutic activity, comparable to that of voriconazole and itracona-
zole (11, 22, 23).
Although the activity of isavuconazole is often comparable to
the activity of voriconazole, it is already known fromphase I and II
studies that isavuconazole has several pharmacokinetic properties
that are advantageous over currently available azoles (14, 15). The
prodrug BAL8557 (or isavuconazonium) is water soluble in
contrast to currently used triazoles, including itraconazole and
voriconazole, which require cyclodextrin to achieve solubility.
Furthermore, the prodrug is rapidly converted into the active
compound BAL4815, which has a longer half-life than other
currently available triazoles. Also, its toxicity is lower than ke-
toconazole or itraconazole, and it has extensive tissue distribu-
tion and high plasma binding capacity (15). Isavuconazole is un-
der investigation in different phase III studies on the safety and
efficacy in treatment of fungal infections caused by Candida spp.,
Aspergillus spp., other filamentous fungi, rare molds, yeasts, and
dimorphic fungi (ClinicalTrials.gov identifiers NCT00413218,
NCT00634049, and NCT00412893). Furthermore, in the study
published by Schmitt-Hoffmann et al., in which both oral and
intravenous treatment regimens in a multiple-dose study in
healthy volunteers were tested, excellent bioavailability withmax-
imum drug concentration levels in serum of 1.85 g/ml was
found (15). This serum level is much higher than the MICs ob-
tained for M. mycetomatis in the present study (MIC90 of 0.063
g/ml). These studies will give us a good understanding whether
isavuconazole has an equal or even better therapeutic efficacy than
the currently used azoles in the treatment of invasive fungal infec-
tions.
In conclusion, isavuconazole appears highly active against M.
mycetomatiswith significantly lowerMICs than theMICs of keto-
conazole.While no clinical data are available yet, the known phar-
macokinetic properties of isavuconazole and the data presented in
the current report suggest that isavuconazole is a promising anti-
fungal agent in the treatment of mycetoma caused by M. mycet-
omatis.
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